Title: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma
- Principal Investigator: Dr. Eric Knoche
- Study Coordinators: Maureen Dempsey and Inessa Sullivan
The CARPET clinical trial is a research study focused on a specific type of advanced prostate cancer. This study evaluates a potential new treatment for veterans with HER2-positive metastatic castration-resistant prostate cancer (mCRPC).
Purpose of the Study
The primary goal of the CARPET trial is to determine the efficacy of the investigational drug T-DXd in patients whose cancer has progressed despite previous treatments. The study will assess the treatment’s effectiveness in individuals who have not responded to androgen deprivation therapy, novel hormonal agents like Abiraterone and Enzalutamide, or for whom taxane-based chemotherapy is not a viable option.
Key Eligibility Criteria
Participation in this study is open to individuals who meet specific criteria. Key qualifications include:
- A diagnosis of HER2-positive metastatic castration-resistant prostate cancer (mCRPC).
- Cancer has progressed after treatment with androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide).
- Patients who have either progressed on, refused, or are not candidates for taxane-based chemotherapy.
This study is administered by VREF and funded by Daiichi-Sankyo, Inc. / ICR
Find Out More
If you are a veteran receiving care through the VA St. Louis Health Care System and believe you may be eligible for this study, please speak with your oncologist. For general information about our research, please visit our main Clinical Trials page or contact us directly.